Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

written by reader CFRX – just announcing OK results for Phase I

By maddogdne, September 18, 2016

Hello all –
Just hoping to perhaps draw Dr. KSS out regarding his view of this company. They are working on using lysins from bacteriophage as antibiotic compounds. Lysins are complex proteins, which I presume they are producing by recombinant DNA tech, but the exquisite specificity of the phage is lost when just the lysin is created. So insofar as I can find, these lysins are entirely nonspecific in their attack on bacterial cell walls, so they will likely have as big a negative impact on our microbiome as they do on the pathogens. I would be a strong supporter of anyone attempting to develop ultra-narrow-spectrum antibiotic compounds with high specificity for pathogens, but another broad spectrum antibiotic compound I think we don’t need, as it will lay waste our pivotally-important natural microbiome in the process of hitting the pathogen(s), thus providing few real new advantages.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

1 Comment
Inline Feedbacks
View all comments
SoGiAm
5 years ago

$CFRX np – you are on target maddogdne…junk, nonsense. http://www.sgumdev.stockgumshoe.com/2015/01/the-long-case-for-receptos/#comment-4198855

👍 11466

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info